Is evantumumab effective in treating the disease?

Introduction: Amivantamab-vmjw is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed with surgery and that has worsened during or after treatment with platinum-based chemotherapy drugs. Evantumumab belongs to a class of drugs called bispecific antibodies, which help the immune system slow or stop the growth of cancer cells.

Can the generic version of evantumumab also be effective in treating diseases?

The generic version of evantumumab refers to a humanized antibody drug produced through biosimilar technology that has similar efficacy and safety to the original biological drug evantumumab. The clinical efficacy and safety of the generic drug are equivalent to that of the original drug. However, as of now, there is no generic version of , so it is impossible to specifically judge the efficacy of the generic version of Evantumumab.

Evantumumab is a bispecific antibody targeting EGFR and MET, used to treat selected patients with non-small cell lung cancer. Because evantumumab is a biologic, the development and production of its generic version requires complex biotechnology and must pass strict quality and efficacy testing to ensure its consistency with the original drug. Based on similar biosimilar research trends, the generic version of evantumumab that follows strict production and quality control standards should be basically the same as the original drug in terms of clinical efficacy and safety, and can also effectively treat diseases.

Efficacy of evantumumab

In a phase 2, open-label, multicenter, multi-cohort clinical trial, the efficacy of evantumumab 10 mg was evaluated in 99 patients with 3L+ES-SCLC who had disease progression after platinum-based chemotherapy and at least one other prior therapy, ECOG PS 0–1, and ≥1 measurable lesion. The study showed that the overall response rate (ORR) of patients was 40%, the median duration of response (mDOR) was 9.7 months, and 68% of patients had a response time of ≥6 months.

Drug Precautions

1. Patients receiving evantumumab may develop cytokine release syndrome (CRS), including severe or life-threatening reactions. Treatment with evantumumab should be initiated using an escalating dose regimen to reduce the incidence and severity of CRS. Depending on severity, withhold evantumumab until resolution of CRS or permanent discontinuation.

2. Patients receiving evantumumab may experience neurotoxicity, including immune effector cell-associated neurotoxic syndrome (ICANS), including severe or life-threatening reactions. Monitor patients for signs and symptoms of neurotoxicity, including ICANS, during treatment and treat promptly. Withhold evantumumab until ICANS resolves or permanently discontinue based on severity.